CA3100312A1 - Manipulating arid5b expression in immune cells to promote metabolism, survival, and function - Google Patents
Manipulating arid5b expression in immune cells to promote metabolism, survival, and function Download PDFInfo
- Publication number
- CA3100312A1 CA3100312A1 CA3100312A CA3100312A CA3100312A1 CA 3100312 A1 CA3100312 A1 CA 3100312A1 CA 3100312 A CA3100312 A CA 3100312A CA 3100312 A CA3100312 A CA 3100312A CA 3100312 A1 CA3100312 A1 CA 3100312A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- arid5b
- population
- immune cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670962P | 2018-05-14 | 2018-05-14 | |
| US62/670,962 | 2018-05-14 | ||
| PCT/US2019/031296 WO2019221991A1 (en) | 2018-05-14 | 2019-05-08 | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3100312A1 true CA3100312A1 (en) | 2019-11-21 |
Family
ID=68540927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100312A Pending CA3100312A1 (en) | 2018-05-14 | 2019-05-08 | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12109236B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793574A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021523717A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112888446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019269318A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100312A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019221991A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7793517B2 (ja) * | 2019-11-28 | 2026-01-05 | アムニオティクス・アーベー | ソース細胞から決定的造血細胞を生成する方法 |
| CN111733154B (zh) * | 2020-04-30 | 2022-11-04 | 和也健康科技有限公司 | 磁场处理的免疫细胞及其用途 |
| KR20230042671A (ko) * | 2020-05-28 | 2023-03-29 | 바이오마그네틱 솔루션스 엘엘씨 | 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법 |
| EP4419541A4 (en) * | 2021-10-21 | 2025-12-17 | Univ Texas | METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| US6448717B1 (en) | 2000-07-17 | 2002-09-10 | Micron Technology, Inc. | Method and apparatuses for providing uniform electron beams from field emission displays |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| EP3349770A1 (en) * | 2015-09-14 | 2018-07-25 | Regents of the University of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| US20180371052A1 (en) | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| EP3452580B1 (en) | 2016-05-02 | 2023-08-16 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
-
2019
- 2019-05-08 CA CA3100312A patent/CA3100312A1/en active Pending
- 2019-05-08 AU AU2019269318A patent/AU2019269318A1/en not_active Abandoned
- 2019-05-08 US US17/055,525 patent/US12109236B2/en active Active
- 2019-05-08 JP JP2020564104A patent/JP2021523717A/ja active Pending
- 2019-05-08 EP EP19803724.4A patent/EP3793574A4/en not_active Withdrawn
- 2019-05-08 WO PCT/US2019/031296 patent/WO2019221991A1/en not_active Ceased
- 2019-05-08 CN CN201980046610.6A patent/CN112888446A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210154232A1 (en) | 2021-05-27 |
| AU2019269318A1 (en) | 2021-01-07 |
| JP2021523717A (ja) | 2021-09-09 |
| EP3793574A4 (en) | 2022-03-09 |
| EP3793574A1 (en) | 2021-03-24 |
| WO2019221991A1 (en) | 2019-11-21 |
| CN112888446A (zh) | 2021-06-01 |
| US12109236B2 (en) | 2024-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kreisel et al. | Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis | |
| Chen et al. | Induction of myelodysplasia by myeloid-derived suppressor cells | |
| Lento et al. | Loss of β-catenin triggers oxidative stress and impairs hematopoietic regeneration | |
| US12109236B2 (en) | Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function | |
| Ranjan et al. | Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells | |
| Jia et al. | Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs | |
| Jia et al. | Indispensable role of Galectin-3 in promoting quiescence of hematopoietic stem cells | |
| Jackson et al. | The Haematopoietically-expressed homeobox transcription factor: roles in development, physiology and disease | |
| EP1567008A2 (en) | Protection of stem cells from cytotoxic agents by modulation of beta-catenin signaling pathways | |
| Bae et al. | Phc2 controls hematopoietic stem and progenitor cell mobilization from bone marrow by repressing Vcam1 expression | |
| EP3600418A1 (en) | Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation | |
| US20160046946A1 (en) | Targeting chromatin modifiers for the treatment of medical conditions | |
| Kim et al. | Alopecia areata: from immunopathogenesis to emerging therapeutic approaches | |
| Saka et al. | Chromatin factor YY1 controls fetal hematopoietic stem cell migration and engraftment in mice | |
| Bellantuono et al. | Stem cell ageing: does it happen and can we intervene? | |
| Won et al. | A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages | |
| HK40044945A (en) | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function | |
| Xiong et al. | The experimental research of pregnancy immune tolerance induced by FTY720 via blocking S1P signal transduction pathway | |
| CN105473710A (zh) | 同源盒转录因子VentX调控人树突状细胞的分化和成熟 | |
| Mammadli et al. | Inhibition of ITK differentiates GVT and GVHD in allo-HSCT | |
| Arizkane | Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission | |
| Rodella | Svelare l'origine specifica cellulare di Oncostatina M (OSM) nel rilascio di cellule staminali ematopoietiche (HSPCs) | |
| Horwitz | Uncovering key determinants of skeletal muscle repair | |
| Arnold | Epigenetic Regulation in Normal and Malignant Hematopoiesis | |
| Di Bella | The PERK (s) of having your own niche: how Acute Myeloid Leukaemia transforms the Bone Marrow Microenvironment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20241108 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20251110 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260221 |